NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.

Trial Details

NCT ID
NCT06941857
Phase
PHASE2
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Oxaliplatin
  • Irinotecan
  • Folinic Acid
  • 5-Fluorouracil (5-FU)
  • NC410
  • Nivolumab
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
  • Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
  • Have metastatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →